AnaptysBio Inc (OQ:ANAB)

Mar 11, 2024 04:15 pm ET
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2023 and provided a business...
Feb 29, 2024 09:15 am ET
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD...
Jan 31, 2024 09:15 am ET
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual...
Nov 27, 2023 04:15 pm ET
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced an exclusive license agreement for Centessa Pharmaceuticals’ (NASDAQ: CNTA) blood dendritic cell...
Nov 11, 2023 07:55 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AnaptysBio, Inc. (NASDAQ: ANAB) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating AnaptysBio, Inc. (NASDAQ: ANAB) (“AnaptysBio”) on behalf of the company’s investors. Since November 2022, shares of AnaptysBio’s common stock have declined in value from a trading price of over...
Nov 07, 2023 04:15 pm ET
Anaptys Named a BioSpace 2024 Best Places to Work Winner
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that, for the second year in a row, it has been named a BioSpace 2024 Best Place to Work in the small...
Nov 07, 2023 12:33 am ET
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into AnaptysBio, Inc.; Urges AnaptysBio’s Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC is investigating AnaptysBio, Inc. (Nasdaq: ANAB) (“AnaptysBio” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether AnaptysBio’s board of directors has violated its fiduciary duty...
Nov 02, 2023 04:15 pm ET
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update....
Nov 01, 2023 09:15 am ET
Anaptys Announces Participation in November Investor Conferences
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior...
Oct 11, 2023 09:15 am ET
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress...
Oct 09, 2023 08:15 am ET
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody,...
Oct 09, 2023 08:00 am ET
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of...
Sep 18, 2023 04:15 pm ET
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. “We are excited to...
Sep 12, 2023 09:15 am ET
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer,...
Aug 07, 2023 04:15 pm ET
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update. "We have...
Jul 31, 2023 01:34 pm ET
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly)...
May 30, 2023 04:15 pm ET
AnaptysBio Announces Participation in Upcoming Investor Conferences
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of...
May 11, 2023 04:15 pm ET
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates. “We’re...
May 02, 2023 09:15 am ET
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy,...
Apr 06, 2023 04:15 pm ET
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately....
Mar 27, 2023 06:50 pm ET
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survi
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial...
Mar 01, 2023 04:05 pm ET
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2022 and provided business...
Feb 27, 2023 04:05 pm ET
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company...
Jan 13, 2023 09:00 am ET
AnaptysBio Announces Stock Repurchase Plan
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may...
Jan 05, 2023 04:05 pm ET
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced a portfolio update including initiating development of its wholly owned best-in-class immune cell...
Dec 02, 2022 09:00 am ET
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI (dostarlimab) plus standard of care...
Nov 21, 2022 01:56 pm ET
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside...
Nov 09, 2022 02:10 pm ET
AnaptysBio to Participate in Upcoming November Investor Conferences
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at...
Nov 08, 2022 04:05 pm ET
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2022 and provided pipeline updates. “We...
Oct 05, 2022 09:00 am ET
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s study PERLA, a head-to-head trial of JEMPERLI vs. Keytruda in patients with metastatic...
Sep 26, 2022 08:00 am ET
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie” Topper, M.D., Ph.D.,...
Sep 12, 2022 07:30 am ET
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned...
Aug 31, 2022 04:15 pm ET
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced top-line data from its HARP Phase 2 trial for the treatment of moderate-to-severe hidradenitis...
Aug 08, 2022 04:05 pm ET
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2022 and provided pipeline updates. “We are...
Aug 05, 2022 04:00 pm ET
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will...
Jun 02, 2022 04:05 pm ET
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga,...
May 04, 2022 04:15 pm ET
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results...
Apr 27, 2022 04:15 pm ET
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today...
Mar 21, 2022 04:15 pm ET
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Mar 14, 2022 04:20 pm ET
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Mar 07, 2022 08:50 am ET
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Jan 06, 2022 08:00 am ET
Recludix Pharma Announces Scientific Advisory Board
Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the establishment of its scientific advisory board. “We are thrilled to have established a group of...
Jan 05, 2022 04:05 pm ET
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Nov 29, 2021 04:05 pm ET
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Nov 15, 2021 07:24 pm ET
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Nov 15, 2021 09:00 am ET
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Nov 04, 2021 04:05 pm ET
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Oct 25, 2021 04:37 pm ET
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Oct 02, 2021 12:00 pm ET
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Sep 09, 2021 04:05 pm ET
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Aug 17, 2021 04:32 pm ET
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Aug 09, 2021 04:05 pm ET
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
May 27, 2021 04:15 pm ET
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
May 04, 2021 04:05 pm ET
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Apr 23, 2021 10:31 am ET
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Apr 22, 2021 04:12 pm ET
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Apr 12, 2021 04:00 pm ET
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Mar 08, 2021 08:00 am ET
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Feb 25, 2021 04:05 pm ET
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Jan 07, 2021 04:15 pm ET
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Nov 13, 2020 09:25 am ET
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Nov 04, 2020 04:00 pm ET
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Oct 26, 2020 08:00 am ET
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Oct 13, 2020 09:00 am ET
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Sep 11, 2020 04:05 pm ET
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Sep 01, 2020 07:36 pm ET
ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating AnaptysBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AnaptysBio, Inc. (NASDAQ: ANAB) on behalf of long-term stockholders. Our investigation concerns whether the board of...
Aug 24, 2020 09:30 am ET
Shuman Glenn & Stecker Investigates AnaptysBio, Inc.
Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (Nasdaq:
Aug 10, 2020 08:05 am ET
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Aug 10, 2020 08:00 am ET
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immune-oncology indications, today reported...
Aug 05, 2020 04:05 pm ET
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jul 31, 2020 08:30 am ET
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Jul 15, 2020 08:30 am ET
AnaptysBio Expands Executive Leadership Team
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Jul 08, 2020 04:05 pm ET
AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Jul 02, 2020 08:48 pm ET
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
SAN DIEGO, July 2, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below.
May 27, 2020 07:33 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
May 25, 2020 10:50 pm ET
ANAPTYSBIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against AnaptysBi
NEW ORLEANS, May 25, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company's shares between October 10, 2017 and November 7, 2019, both dates inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of California.
May 25, 2020 01:00 pm ET
ANAB DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds AnaptysBio, Inc. Shareholders with Losses in Excess of $100,000 of Class Action and Lead Plaintiff Deadline: May 26, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders...
May 25, 2020 10:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AnaptysBio, Inc. (ANAB)
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
May 22, 2020 10:50 pm ET
ANAPTYSBIO 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against AnaptysBi
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company’s shares between October 10, 2017 and November 7, 2019, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
May 22, 2020 03:00 pm ET
DEADLINE ALERT for ANAB, DOYU, HAFC, and HFFG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 22, 2020 11:18 am ET
ANAB FINAL DEADLINE TUESDAY: ROSEN, A TOP RANKED INVESTOR FIRM, Reminds AnaptysBio, Inc. Investors of Important May 26 Deadline in Securities Class Action
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
May 21, 2020 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
May 21, 2020 03:00 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AnaptysBio, Inc. Investors (ANAB)
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ:
May 21, 2020 01:00 pm ET
ANAB DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds AnaptysBio, Inc. Shareholders with Losses in Excess of $100,000 of Class Action and Lead Plaintiff Deadline: May 26, 2020
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AnaptysBio securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
May 21, 2020 12:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB)  investors who...
May 20, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017 -...
May 20, 2020 11:30 am ET
DEADLINE ALERT for XELA, ANAB, I, BBBY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 19, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB, BIDU, GRPN and LOPE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. AnaptysBio, Inc. (ANAB)Investors Affected: October 10, 2017 and November 7, 2019Lead Plaintiff Motion Deadline:...
May 19, 2020 04:34 pm ET
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 19, 2020 01:00 pm ET
ANAB DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds AnaptysBio, Inc. Shareholders with Losses in Excess of $100,000 of Class Action and Lead Plaintiff Deadline: May 26, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders...
May 18, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, LOPE, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017 - 11/7/2019Lead Plaintiff Motion Deadline: May 26,...
May 18, 2020 08:33 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AnaptysBio (ANAB) Investors: 8-DAY DEADLINE ALERT in Securities Class Action, Investors with Losses Should Contact its Attorneys
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  The May 26, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company...
May 18, 2020 02:20 pm ET
ANAB INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Reminds AnaptysBio, Inc. Investors of Important May 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
May 17, 2020 12:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
May 15, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017 -...
May 15, 2020 03:45 pm ET
ANAPTYSBIO LOSS NOTICE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Reminds AnaptysBio, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $10
NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
May 14, 2020 09:27 am ET
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 13, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP) Class Period: shares issued in connection with its December 2019 Initial Public...
May 12, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB, BIDU and GRPN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. AnaptysBio, Inc. (ANAB)Investors Affected: October 10, 2017 and November 7, 2019Lead Plaintiff Motion Deadline:...
May 12, 2020 07:35 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: TWO WEEK DEADLINE ALERT in Securities Fraud Class Action
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  The May 26, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company...
May 12, 2020 11:30 am ET
DEADLINE ALERT for XELA, ANAB, I, BBBY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 11, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017...
May 10, 2020 11:57 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
May 08, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
May 08, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB)  investors who...
May 08, 2020 11:02 am ET
ANAPTYSBIO LOSS ALERT: ROSEN, A TOP RANKED FIRM, Reminds AnaptysBio, Inc. Investors to Contact Firm Prior to May 26 Deadline for Class Action Seeking Recovery of Investor Losses – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
May 06, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017 -...
May 06, 2020 04:05 pm ET
AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
May 05, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB and GRPN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. AnaptysBio, Inc. (ANAB)Investors Affected: October 10, 2017 and November 7, 2019Lead Plaintiff Motion Deadline:...
May 05, 2020 11:30 am ET
DEADLINE ALERT for XELA, ANAB, I, BBBY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 04, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
May 03, 2020 01:15 pm ET
ANAB ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Investors of AnaptysBio, Inc. to Contact the Firm Prior to the Important Deadline in Suit Seeking Recovery of Investor Losses – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
May 01, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017 -...
May 01, 2020 01:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 30, 2020 07:15 pm ET
ANAB LOSS NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Anaptysbio, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Con
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
Apr 30, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB) investors who...
Apr 29, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 29, 2020 07:26 pm ET
Shareholder Alert: Robbins LLP Announces It Is Investigating AnaptysBio, Inc. (ANAB) for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that it is investigating AnaptysBio, Inc. (NASDAQ: ANAB) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. AnaptysBio is a clinical stage biotechnology company that eng
Apr 28, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB, TLRY and WWE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Tilray, Inc. (TLRY) Investors Affected: January 15, 2019 - March 2, 2020Lead Plaintiff Motion Deadline: May 5,...
Apr 28, 2020 12:00 pm ET
RTIX & ANAB INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 27, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017 -...
Apr 24, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 23, 2020 10:35 am ET
ROSEN, A TOP RANKED LAW FIRM, Reminds AnaptysBio, Inc. Investors of Important Deadline in Securities Class Action – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
Apr 23, 2020 01:11 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 22, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017...
Apr 22, 2020 04:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTI Surgical Holdings, Inc. (NADAQ: RTIX), AnaptysBio, Inc. (NASDAQ: ANAB),...
Apr 21, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALGN, ANAB, TLRY and WWE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Align Technology, Inc. (ALGN)Investors Affected: April 24, 2019 – July 24, 2019Lead Plaintiff Motion Deadline:...
Apr 20, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, BBBY, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 17, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017...
Apr 17, 2020 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB) investors who...
Apr 15, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP) Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 15, 2020 09:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Apr 15, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTI Surgical Holdings, Inc. (NADAQ: RTIX), AnaptysBio, Inc. (NASDAQ: ANAB),...
Apr 15, 2020 12:12 pm ET
Zhang Investor Law Announces Securities Class Action Lawsuit Against AnaptysBio, Inc – ANAB
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). If you wish to serve as lead...
Apr 14, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALGN, ANAB, TLRY and WWE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Align Technology, Inc. (ALGN)Investors Affected: April 24, 2019 – July 24, 2019Lead Plaintiff Motion Deadline:...
Apr 13, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017...
Apr 12, 2020 02:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
NEW YORK, April 12, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 12, 2020 02:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
NEW YORK, April 12, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 10, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP) Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 10, 2020 08:15 pm ET
ANAB Loss Notice: Rosen, a Top Firm, Reminds AnaptysBio, Inc. Investors With Large Losses of the May 26 Deadline in the Class Action Seeking Recovery of Investor Losses – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
Apr 10, 2020 01:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
Apr 10, 2020 12:19 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Apr 09, 2020 12:37 pm ET
Shareholder Alert: Robbins LLP Reminds Investors AnaptysBio, Inc. (ANAB) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of AnaptysBio, Inc. (NASDAQ: ANAB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 10, 2017 and November 7, 2019. AnaptysBio is a clinical stage biotechnology company that e
Apr 08, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, SIX INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Six Flags Entertainment Corporation (SIX)Class...
Apr 08, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTI Surgical Holdings, Inc. (NADAQ: RTIX), AnaptysBio, Inc. (NASDAQ: ANAB),...
Apr 08, 2020 11:30 am ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AnaptysBio, Inc. (ANAB)
Law Offices of Howard G. Smith reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) securities between October 10, 2017 and November 7, 2019, inclusive (the “Class P
Apr 07, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB and XP
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. XP, Inc. (XP)Investors Affected: Shares issued in connection with the December 2019 initial public stock...
Apr 07, 2020 04:11 pm ET
ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for
NEW YORK and SAN DIEGO, April 7, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in United States District Court for Southern District of California on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period").
Apr 06, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 03, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, SIX INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Six Flags Entertainment Corporation (SIX)Class...
Apr 02, 2020 08:44 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: Securities Fraud Class Action Filed, Important Deadlines Established
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  A securities class action has been filed, and certain investors may have valuable claims.  Class Period: Oct. 10,...
Apr 02, 2020 10:00 am ET
ANAB SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies AnaptysBio, Inc. Shareholders of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AnaptysBio securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 01, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, SSL, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Sasol Limited (SSL) Class Period: 3/10/2015 - 1/13/2020Lead Plaintiff Motion Deadline: April 6,...
Apr 01, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exela Technologies, RTI Surgical, DouYu, and AnaptysBio and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Exela Technologies, Inc. (NADAQ: XELA), RTI Surgical Holdings, Inc. (NADAQ:...
Apr 01, 2020 06:23 pm ET
ANAPTYSBIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for
Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in United States District Court for Southern District of California on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or "the...
Mar 31, 2020 07:15 pm ET
ANAB Stock: Berger Montague Investigates Securities Fraud Class Action Claims Against AnaptysBio, Inc. (NASDAQ: ANAB); Lead Plaintiff Deadline is May 26, 2020
PHILADELPHIA, March 31, 2020 /PRNewswire/ -- Berger Montague is investigating securities fraud claims against AnaptysBio, Inc. ("AnaptysBio" or the "Company") on behalf of all purchasers of AnaptysBio common stock (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019 (the "Class Period").
Mar 31, 2020 07:00 pm ET
ANAPTYSBIO SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company’s shares between October 10, 2017 and November 7, 2019, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
Mar 31, 2020 11:15 am ET
ANAB LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against AnaptysBio, Inc.; Encourages Investors with Large Losses to Contact Firm – ANAB
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class...
Mar 31, 2020 10:00 am ET
ANAB SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies AnaptysBio, Inc. Shareholders of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
NEW YORK, March 31, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AnaptysBio securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/anab.        
Mar 30, 2020 11:01 pm ET
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in AnaptysBio, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 30, 2020 03:00 pm ET
ANAB SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies AnaptysBio, Inc. Shareholders of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders...
Mar 30, 2020 11:02 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Mar 27, 2020 07:45 pm ET
ANAB ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against AnaptysBio, Inc. - ANAB
NEW YORK, March 27, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
Mar 27, 2020 05:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of AnaptysBio, Inc. (ANAB) Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
Mar 27, 2020 04:14 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: Securities Fraud Class Action Filed
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  A securities class action has been filed, and certain investors may have valuable claims.  Class Period: Oct. 10,...
Mar 27, 2020 03:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf AnaptysBio, Inc. (ANAB) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) securities between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). AnaptysBio investors have until May 26, 2020 to fil
Mar 27, 2020 02:03 pm ET
Shareholder Alert: Robbins LLP Announces AnaptysBio, Inc. (ANAB) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of AnaptysBio, Inc. (NASDAQ: ANAB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 10, 2017 and November 7, 2019. AnaptysBio is a clinical stage biotechnology company that engages in develo
Mar 27, 2020 12:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of AnaptysBio Inc. Investors (ANAB)
The Law Offices of Frank R. Cruz announces an investigation on behalf of AnaptysBio Inc. ("AnaptysBio" or the "Company") (NASDAQ:
Mar 27, 2020 11:39 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against AnaptysBio, Inc. (ANAB)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB) in the United States District Court for the Southern District of California on behalf of those...
Mar 27, 2020 10:00 am ET
ANAB Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AnaptysBio, Inc. and Encourages Investors to Contact the Firm
NEW YORK, March 27, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB). Investors who purchased AnaptysBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/anab.
Mar 27, 2020 09:00 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AnaptysBio, Inc. (“AnaptysBio” or “the Company”) (NASDAQ:
Mar 27, 2020 07:46 am ET
AnaptysBio (ANAB) Class Action Alert: Johnson Fistel Encourages Investors to Contact Firm
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB). The class action is on behalf of shareholders who...
Mar 26, 2020 09:21 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: Securities Fraud Class Action Filed
SAN FRANCISCO, March 26, 2020 /PRNewswire/ -- Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  A securities class action has been filed, and certain investors may have valuable claims. 
Mar 26, 2020 06:39 pm ET
ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AnaptysBio, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased AnaptysBio, Inc. (NASDAQ: ANAB) securities between August 10, 2017 and November 7, 2019 (the “Class Period”). Investors have until May 26, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 26, 2020 06:30 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AnaptysBio, Inc. (ANAB) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
Mar 26, 2020 04:44 pm ET
AnaptysBio (ANAB) Class Action Alert: Johnson Fistel Encourages Investors to Contact Firm
SAN DIEGO, March 26, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of AnaptysBio, Inc. ("AnaptysBio" or the Company")(NASDAQ: ANAB). The class action is on behalf of shareholders who purchased AnaptysBio common stock between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than May 26, 2020. 
Mar 26, 2020 04:40 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AnaptysBio, Inc. (ANAB) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) investors concerning the Company and its officers’ possible violations of federal securities laws.
Mar 26, 2020 03:08 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AnaptysBio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. (“AnaptysBio” or “the Company”) (NASDAQ:
Mar 26, 2020 10:49 am ET
ANAB Stock - Class Action Lawsuit Filed Against AnaptysBio, Inc. on Behalf of Purchasers or Acquirers of ANAB Stock Between October 10, 2017 and November 7, 2019, Both Dates Inclusive - Kehoe Law Firm
PHILADELPHIA, March 26, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C. is making investors aware that a class action lawsuit was filed on March 25, 2020 in United States District Court, Southern District of California, against AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NasdaqGS: ANAB) on behalf of individuals or entities who purchased, or otherwise acquired, ANAB securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period").  The securities class action was brought against AnaptysBio and certain of its current and former senior executives under Sections 10(b) and
Mar 26, 2020 09:22 am ET
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against AnaptysBio, Inc. – ANAB
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
Mar 25, 2020 08:55 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AnaptysBio, Inc. (“AnaptysBio” or “the Company”) (NASDAQ:
Mar 02, 2020 08:45 am ET
AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Feb 25, 2020 04:00 pm ET
AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jan 08, 2020 04:00 pm ET
AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Nov 08, 2019 08:05 am ET
AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30,...
Nov 08, 2019 08:00 am ET
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized,...
Sep 30, 2019 04:15 pm ET
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline data from an interim analysis of its...
Sep 27, 2019 06:30 am ET
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Aug 08, 2019 04:15 pm ET
AnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the second quarter ended June 30,...
Aug 06, 2019 06:30 am ET
AnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jun 05, 2019 07:00 am ET
AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today presented updated proof-of-concept data for etokimab, its...
May 28, 2019 06:55 am ET
AnaptysBio to Present at the Jefferies 2019 Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
May 07, 2019 04:15 pm ET
AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31,...
May 01, 2019 06:30 am ET
AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Mar 04, 2019 06:30 am ET
AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Feb 28, 2019 05:45 am ET
AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the fourth quarter and year ended...
Jan 02, 2019 06:30 am ET
AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Nov 26, 2018 08:00 am ET
Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ebix, Inc. (NASDAQ:EBIX), Gold Resource Corporation (NYSE:GORO), Mastech...
Nov 08, 2018 04:15 pm ET
AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.